The low immunogenicity of tumor cells is one of the key mechanisms used by the tumor to escape from the immune surveillance. Thus, new cancer immunotherapeutic strategies aim at enhancing the presentation of tumor antigens to T cells. To this end, therapeutic cancer vaccines are an attractive alternative to conventional therapies (chemotherapy, immune checkpoints inhibitors, etc). We validated at Explicyte a model of immunization relying on the co-administration of adjuvants poly(I:C) (TLR3 ligand) and agonistic anti-CD40 antibody into tumor bearing mice. This immunization approach represents an attractive model to evaluate the capacity of drug candidates to boost the anti-tumor immunity.